Form 8-K - Current report:
SEC Accession No. 0001551152-25-000011
Filing Date
2025-01-31
Accepted
2025-01-31 07:42:37
Documents
16
Period of Report
2025-01-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abbv-20250131.htm   iXBRL 8-K 39546
2 EX-99.1 abbv-20241231xexhibit991.htm EX-99.1 505455
7 abbvieimage1a53.jpg GRAPHIC 15145
  Complete submission text file 0001551152-25-000011.txt   805397

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abbv-20250131.xsd EX-101.SCH 3730
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT abbv-20250131_def.xml EX-101.DEF 19667
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abbv-20250131_lab.xml EX-101.LAB 35738
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abbv-20250131_pre.xml EX-101.PRE 20328
18 EXTRACTED XBRL INSTANCE DOCUMENT abbv-20250131_htm.xml XML 8572
Mailing Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064
Business Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 (847) 932-7900
AbbVie Inc. (Filer) CIK: 0001551152 (see all company filings)

EIN.: 320375147 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35565 | Film No.: 25575942
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)